Revenue and profitability:
- Revenue (Q2 2024, USD): $662,715. YoY growth shown as 569.8% in the dataset, with QoQ not disclosed (N/A).
- Gross Profit (Q2 2024, USD): $662,715, implying a gross margin near 100% in the quarter per the quarterly data, though the broader data set shows substantial cost of revenue in other views.
- Operating Income (Q2 2024, USD): $(3,704,000). EBITDA (Q2 2024, USD): $(3,231,000). These reflect substantial R&D and G&A investments relative to the modest top line.
- Net Income (Q2 2024, USD): $(1,943,000). EPS (basic): $(221.40).
- Cash flow: Net cash used in operating activities $(3,358,087); net change in cash $(3,746,341); cash at end of period $(4,418,560).
- Liquidity and liquidity metrics (Q2 2024): Current ratio 3.81; Quick ratio 3.95; Cash ratio 3.36; net debt ladder shows a negative net debt (net cash) position in the balance sheet view, with cash on hand and limited near-term debt.
Balance sheet and capitalization:
- Total assets: approximately $26.48 million. Total liabilities: approximately $6.69 million. Total stockholders’ equity: approximately $19.79 million.
- Cash and cash equivalents (balance sheet view): approximately $10.13 million.
- Long-term debt: around $0.27 million; total debt around $1.07 million; net debt reported as negative (net cash) in the balance sheet view, suggesting liquidity headroom despite burn.
- Intangibles and goodwill: goodwill approximately $8.83 million; intangible assets around $5.80 million; total goodwill and intangible assets roughly $14.63 million, contributing to a substantial non-cash asset base that may support licensing discussions or potential impairment considerations in more volatile periods.
Narrative takeaway:
- The quarter confirms Bionomics’ status as an early-stage biotech with minimal revenue and a high fixed cost base driven by R&D and corporate overhead. The cash burn is material relative to revenue, pressuring the balance sheet to rely on existing cash and potential external financing or licensing agreements to extend the runway. The company’s pipeline, together with a Merck licensing arrangement noted in public descriptions, represents potential value creation if a partner milestone or financing event occurs. Absent a near-term commercial catalyst or a favorable financing event, investors should be prepared for continued reliance on dilutionary financing or milestone-based partnerships to fund ongoing trials and platform development.